Almas Bashir Research & Editorial Office opened at PINS
The Chief Guest of the ceremony was Dr. Almas Bashir. Executive Director PINS Prof. Dr. Asif Bashir, Principal Ameer uddin Medical College Prof. Dr. Farooq Afzal and senior professors and health professionals attended the ceremony.
Speaking on the occasion, Prof. Dr. Asif Bashir emphasized that PINS is committed to enhancing healthcare services in collaboration with international institutions. The establishment of the Almas Bashir Research & Editorial Office marks a significant step towards expanding the institute's research initiatives, enabling young doctors and professionals to benefit from dedicated facilities and resources for research and editorial work, he said.
In his address, Prof. Dr. Farooq Afzal underscored the vital role of medical research in the development of healthcare system worldwide. He emphasized that while Pakistan has no shortage of talent, the focus should now be shifted towards self-reliance, urging professionals to contribute actively to research and innovation across all healthcare domains instead of relying solely on external support. He stressed the importance of research in the field of neuroscience, noting that PINS continues to progress steadily in the domain of neurosurgery.
He expressed his confidence that Pakistani surgeons and medical professionals will continue to make the nation proud through excellence in clinical and research fields.
Principal LGH and ED PINS jointly reiterated that institutions are strengthened not by infrastructure alone but through mutual cooperation and cohesive teamwork. They highlighted the inseparable relationship between LGH and PINS, describing it as 'two souls in one body,' both committed to ensuring optimal patient care and clinical services through unified efforts. They reaffirmed their dedication to implementing the health initiatives of Chief Minister Punjab Ms. Maryam Nawaz Sharif by providing integrated treatment platforms for patients at both PINS and LGH.
They stressed that delivering high-quality healthcare to all patients without discrimination remains their shared mission and no effort will be spared in achieving this goal.
Among others, Prof Qasim Bashir, Prof Mohsin Zaheer, Prof Hafiz Abdul Majeed, Prof Shehzad Hussain Shah, Prof Naghmana Mazhar, Prof Saira Bilal, Prof Mudassar Aslam and Medical Superintendent Dr Umar Ishaq were present.
Copyright Business Recorder, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
2 days ago
- Express Tribune
Pakistan, KSA ink $121m deals for health, energy projects
Saudi Ambassador Nawaf bin Said Al-Malki on Friday reaffirmed Riyadh's unwavering support for Pakistan's development journey. Speaking at a ceremony marking the signing of consulting services contracts to support development projects in Pakistan - financed by the Saudi Fund for Development (SFD) - Al-Malki said the projects would provide vital services, boost economic growth, and contribute to the well-being of the Pakistani people. The Saudi Fund for Development (SFD) has signed consultancy service contracts for three major projects in Pakistan — the King Salman Hospital in Tarlai and the Shounter and Jagran hydropower projects in Azad Jammu & Kashmir — with a combined financing package worth $121 million. The King Salman Hospital will be funded through a $20 million grant from the Kingdom of Saudi Arabia, while the Shounter and Jagran hydropower projects will receive concessional loans of $66 million and $35 million respectively.
Business Recorder
3 days ago
- Business Recorder
USA tariff opens up new pharma export avenues
KARACHI: Pakistan's pharmaceutical sector foresees a window of opportunity to enhance its exports manifolds to the United State of America (USA) after announcement of new tariff policy for various countries which provides a competitive edge to Pakistan against neighbouring economies. Pakistan has been imposed a tariff of 19 percent for exporting its goods to the United States of America as compared to 25-50 percent or varying for India and up to 50 percent for China. 'Current favourable tariff structure presents an excellent opportunity for Pakistan's pharmaceutical sector to explore the USA market and earn valuable foreign exchange for the country. However, joint efforts are required to get regulatory approvals from the USA authorities,' said Shahzad Haider a healthcare sector expert and financial advisor. Pakistan's pharma sector export growth hits two-decade high He informed that India and China are two major importers of the medicines of the US market, hence, higher duties on these countries will create a significant room for other countries, including Pakistan to enhance their exports manifolds in the next few years. Data stated that the export of Indian pharmaceutical brands to the USA market stood at more than $8.5 billion and Chinese products stood at over $2.5 billion in 2024. In addition to a competitive advantage of tariff, the USA is presently facing depleting stocks of medicines in its healthcare industry which portraying an immense hike of demands for certain medicine in a major market of the world. 'It is right time that the government and all stakeholders of the pharmaceutical sector should set a roadmap to enter the USA market with its different products and enhance its exports to manifolds with respect to the demand of buyers,' Haider added. He mentioned that Pakistan could leverage its strengthening diplomatic ties with the US and work with its drug regulatory authority for bridging the supplies gap of medicines to its healthcare and wellness sector up to its standards. Pakistani products are capable of meeting the standards of the USA market depending upon the certification from the regulatory authority, Shahzad Haider said. However, Pakistani companies could meet supplies to the US market in a limited quantity due to its capacity constraints, he mentioned. He further said that long-term agreement with the US markets will lead to expansion of Pakistani pharmaceutical units that will attract foreign and domestic investment within the sector, he added. Considering the demands of the USA market, Haider said that, Pakistani pharmaceutical exporters could double the exports of the country within next two years but they require strict adherence to the US Food and Drug Administration (FDA) standards, investment in modern manufacturing facilities, and certification from international regulatory bodies. Dr Kaiser Waheed, former Chairman Pakistan Pharmaceutical Manufac-turers Association (PPMA) said that Pakistan is exporting herbal medicines to the USA market but its quantity could be increased manifold. He mentioned that a number of Pakistan's pharmaceutical products with recognition of the global drug authorities could also explore export potential in the USA market depending upon the approval of the (Food and Drug Administration FDA). He pinned hope that the improving bilateral diplomatic and trade between the USA and Pakistan may help Pakistan's pharmaceutical industry to make inroads in the US market within the next few months. According Pakistan Bureau of Statistics, overall exports of medicines from Pakistan grew by 34 percent to $457 million during FY25the highest ever growth in terms of percentage marking a 20-year high due to deregulation of the sector and innovation. At present, Pakistan exports medicines to 70 countries worldwide in Europe, USA, Central Asia, Africa and other countries. Copyright Business Recorder, 2025
Business Recorder
4 days ago
- Business Recorder
Highnoon Laboratories, Beximco Pharmaceuticals partner to help transform healthcare in Pakistan
Highnoon Laboratories Limited has announced a partnership with Beximco Pharmaceuticals Limited, a pharmaceutical manufacturer based in Bangladesh, stating that the alliance marked a milestone in Highnoon's international expansion strategy, aimed at bringing advanced technologies, therapies, and novel dosage forms to the Pakistani market. Both companies are listed on the stock exchanges in their respective countries. The memorandum of understanding (MoU) was signed at Beximco's headquarters in Dhaka by Dr Adeel Abbas, Co-Chairman & CEO of Highnoon Laboratories Limited, and Mr Rabbur Reza, Chief Operating Officer of Beximco Pharmaceuticals Limited. The partnership will focus on the distribution, marketing, and sales of specialiased pharmaceutical products in Pakistan, with an emphasis on respiratory, diabetes, and cardiovascular therapeutic segments. The collaboration is designed to strengthen Highnoon's portfolio in these high-impact areas, providing a competitive edge through innovative drug delivery systems and clinical advancements, according to the company. Highnoon is listed on the Pakistan Stock Exchange. With cGMP- compliant manufacturing capabilities and a diverse product portfolio across major therapeutic areas, the company continues to position itself as a trusted healthcare partner, both locally and internationally. The collaboration also reflects the strengthening economic ties between Pakistan and Bangladesh, reinforcing a shared vision for regional cooperation in healthcare and trade.
